维普中文期刊产品整合服务
8篇 您的检索式:作者名="Mortada R"
    题名 作者 年代 出处 被引量
1Metabolic Syndrome :Polycystic O- vary Syndrome 显示文摘Mortada R Williams T 2015FP Essent2015,435,:1
2In search of the“LINK”:acute phase serum amyloid A显示文摘Karakas K Mortada R Fellow C 2011Atherosclerosis2011,216,2:1
3Endovascular stent graft repair of abdominal aortic aneurysms in high-risk patients:a single center experience显示文摘Allaqaband S Mortada ME Tumuluri R 2004J Intervent Cardiol2004,17,:1
4Preparation, in vitro and vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy 显示文摘Ishak R A H Awad G A S Mortada N D 2007Journal of Controlled Release2007,119,2:1
5Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies显示文摘HATHOUS R M MANSOUR S MORTADA N D 2007AAPS Pharm Sci Tech2007,8,1:1
6In search of the'LINK' : acute phase serum amyloid A 显示文摘Karakas S Mortada R Fellow C 2011Athero-sclerosis2011,216,2:1
7Endovascular stent graft repair of abdominal aortic aneurysms in high-risk patients:a single center experience显示文摘Allaqaband S Mortada ME Tumuluri R 2004J Interv Cardiol2004,17,2:1
8Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy显示文摘BACKGROUND Childhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV).The effects of all-oral direct-acting antiviral therapy (DAA) on both the HCV infection as well as the state of cancer remission have not been well investigated in this population.AIM To test the effects of dual sofosbuvir/daclatasvir (SOF/DCV) therapy in the treatment of chronic HCV in survivors of hematologic malignancy in pediatric age group.METHODS We conducted a prospective,uncontrolled,open-label multicenter study.A total of 20 eligible,chronic HCV,genotype-4,infected children who had been in continuous complete remission from hematologic cancer (leukemia/lymphoma) for at least one year were included in the study.All patients were treated with combined SOF/DCV for 12 wk.Patients were monitored throughout the study till 12 wk after end of treatment for safety and efficacy outcomes including the sustained virologic response 12 (SVR12) rate,hematological indices,liver and kidney functions.RESULTS The intent-to-treat SVR12 rate was 20 of 20 (100%;95%CI: 84%-100%).All patients showed normalized liver enzymes from week-4.All hematological indices,liver and kidney functions were kept normal throughout the study.No fatalities or treatment-emergent serious or severe adverse events were reported throughout the study.CONCLUSION SOF/DCV combined therapy could be used safely and effectively in the treatment of chronic HCV genotype-4 infection in leukemia/lymphoma treated children.No relapses were detected during treatment and throughout the follow up period for either the original malignant disease or the HCV infection.Mortada HF El-Shabrawi Laila M Sherief Mostafa Yakoot Naglaa M Kamal Mohamed A Almalky Manal M AbdElgawad Aml A Mahfouz Sherine Helmy Enas M Kamal Dina Attia Hisham R El-Khayat 2019World Journal of Clinical Cases2019,7,16:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费